Many adjuvant therapies, such as hydrocortisone (high doses used in the 1970's), thiamine and ascorbic acid, have been suggested to increase blood pressure in severe shock and should be considered when combined vasopressor therapy is needed [3] . Nowadays, vasopressin and methylene blue seems to be the most commonly used drugs as on option for association with high doses of norepinephrine (NE). Vasopressin acts through membrane receptors and methylene, by blocking the NO/cGMP pathway, "crosstalking with the amine-dependent PGI2/cAMP pathway" [4] .
Based on almost 25 years of experimental and clinical experience our opinion is that methylene blue (MB), at present, may be the best, safest, and cheapest option. Even in the absence of definitive multicentric studies, experimental studies suggest a potential protective role of MB in microcirculation. In an experimentallyinduced septic shock model in rats, only the combination of NE + MB restored mean arterial pressure to control levels by the end of the three-hour experiment [5, 6] .
Finally, the current concept should be illustrated by the above mentioned "Jekyll-and-Hyde" analogy. Some remarks should be mentioned based on the "Vasopressor Support Sparing Strategies" paradigm:
1. What is the best drug considering the pharmacological mechanism (membrane receptors, endothelium-dependent mechanisms…)? 2. Precocious "window of opportunity" or even always adopt the support sparing strategies? 3. Search for novel vasopressor agents, such as synthetic human angiotensin II, which would increase blood pressure and reduce the need for high doses of catecholamine vasopressors. 4. Optimistically, if possible, seek new vasopressors that increase the arterial blood pressure without microcirculatory damage.
